&lt;p&gt;Intraarticular Injection of Infliximab-Loaded Thermosensitive Hydrogel Alleviates Pain and Protects Cartilage in Rheumatoid Arthritis&lt;/p&gt;

Chen, Wei‐Ying; Li, Zuhao; Wang, Zhenhong; Gao, Hong; Ding, Junyun; He, Zhenzhou

doi:10.2147/jpr.s283518

Cited by 30 publications

(21 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the RANKL mRNA levels were also decreased in the spleens of the treated mice. The study reporting the benefits of using intra-articular injections of the anti-TNF infliximab, loaded onto thermosensitive hydrogel to decrease pro-inflammatory cytokines within the synovial fluids of a rabbit model of RA induced by ovalbumin and complete Freund's adjuvant, is another example illustrating the interplay between TNF-α and IL-1β in vivo [41]. Indeed, two and six weeks after injections, the intra-articular levels of both TNF-α and IL-1β were significantly decreased, compared with the saline-treated control.…”

Section: Ra and Cytokines: A Tnf-α And Il-1β Crosstalk Modeled Both In Vitro And In Vivomentioning

confidence: 99%

Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH® Micro-Immunotherapy Treatment

Jacques¹,

Floris²,

Lejeune³

2021

IJMS

View full text Add to dashboard Cite

Tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) are two cytokines involved in the perpetuation of the chronic inflammation state characterizing rheumatoid arthritis (RA). Significant advances in the treatment of this pathology have been made over the past ten years, partially through the development of anti-TNF and anti-IL-1 therapies. However, major side effects still persist and new alternative therapies should be considered. The formulation of the micro-immunotherapy medicine (MIM) 2LARTH® uses ultra-low doses (ULD) of TNF-α, IL-1β, and IL-2, in association with other immune factors, to gently restore the body’s homeostasis. The first part of this review aims at delineating the pivotal roles played by IL-1β and TNF-α in RA physiopathology, leading to the development of anti-TNF and anti-IL-1 therapeutic agents. In a second part, an emphasis will be made on explaining the rationale of using multiple therapeutic targets, including both IL-1β and TNF-α in 2LARTH® medicine. Particular attention will be paid to the ULD of those two main pro-inflammatory factors in order to counteract their overexpression through the lens of their molecular implication in RA pathogenesis.

show abstract

Section: Ra and Cytokines: A Tnf-α And Il-1β Crosstalk Modeled Both In Vitro And In Vivomentioning

confidence: 99%

Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH® Micro-Immunotherapy Treatment

Jacques¹,

Floris²,

Lejeune³

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The group administered the tacrolimus-laden Soluplus NPs via subcutaneous injection adjacent to the arthritic joints, and observed a significant reduction in edema within the arthritic paw over time, compared to the same hydrogel without tacrolimus [179]. Chen et al [180] formulated a hydrogel composed of Pluronic F127, poly(γ-glutamic acid), and hyaluronic acid, and encapsulated infliximab, an anti-TNF-α antibody. Through incorporation of infliximab into the hydrogel, Chen and co-authors aim to sequester infliximab within the diseased joint, thereby mitigating systemic suppression of TNF-α [180].…”

Section: Scaffolds Help To Build Therapymentioning

confidence: 99%

“…Chen et al [180] formulated a hydrogel composed of Pluronic F127, poly(γ-glutamic acid), and hyaluronic acid, and encapsulated infliximab, an anti-TNF-α antibody. Through incorporation of infliximab into the hydrogel, Chen and co-authors aim to sequester infliximab within the diseased joint, thereby mitigating systemic suppression of TNF-α [180]. In a rabbit model of ovalbumin (OVA)-induced RA, the group injected the hydrogel intraarticularly 1 week post RA induction.…”

Section: Scaffolds Help To Build Therapymentioning

confidence: 99%

“…In a rabbit model of ovalbumin (OVA)-induced RA, the group injected the hydrogel intraarticularly 1 week post RA induction. After 6 weeks, they observed alleviation of joint pathology and cartilage destruction, as well as a reduction in synovial fluid levels of TNFα, IL-1β, IL-6, and IL-17, compared to the same hydrogel without infliximab [180]. Zhao and co-authors [181] sought to add a healing component to their strategy in addition to alleviation of joint pathology.…”

Section: Scaffolds Help To Build Therapymentioning

confidence: 99%

“…Zhao and co-authors [181] sought to add a healing component to their strategy in addition to alleviation of joint pathology. The group utilized an infliximab-based hydrogel combined with a 3D-printed porous metal scaffold (3DMS) that was seeded with adipose-derived mesenchymal stem cells (ADSCs), where introduction of the ADSCs would aid in the rebuilding of the articular ECM [180]. This scaffold was implanted intra-articularly within the OVA-induced rabbit model and led to amelioration of RA pathology and promoted restoration of cartilage and bone repair [180].…”

Section: Scaffolds Help To Build Therapymentioning

confidence: 99%

See 2 more Smart Citations

Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis

Lewis

2021

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Intra‐Articular Injectable Biomaterials for Cartilage Repair and Regeneration

Kalairaj,

Pradhan,

Saleem

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Osteoarthritis is a degenerative joint disease characterized by cartilage deterioration and subsequent inflammatory changes in the underlying bone. Injectable hydrogels have emerged as a promising approach for controlled drug delivery in cartilage therapies. This review article focuses on the latest developments in utilizing injectable hydrogels as vehicles for precise and targeted drug delivery to promote cartilage repair and regeneration. The review begins by discussing the pathogenesis of osteoarthritis to provide a comprehensive understanding of the disease process. Subsequently, we delve into the various types of injectable hydrogels used for drug delivery to cartilage. Specifically, physically and chemically crosslinked injectable hydrogels are explored, with an emphasis on their fabrication strategies and their capacity to encapsulate and release therapeutic agents in a controlled manner. Furthermore, we discuss the potential of incorporating growth factors, anti‐inflammatory drugs, and stem cells within these hydrogel systems. We highlight their crucial roles in modulating cellular behavior, promoting cartilage regeneration, and reducing inflammation. Overall, this review offers a comprehensive guide to navigating the promising landscape of hydrogel‐based therapeutics in osteoarthritis. By providing insights into the pathogenesis of osteoarthritis and discussing the advancements in injectable hydrogels for controlled drug delivery, this review aims to enhance our understanding and foster further developments in the field of cartilage repair and regeneration.This article is protected by copyright. All rights reserved

show abstract

<p>Intraarticular Injection of Infliximab-Loaded Thermosensitive Hydrogel Alleviates Pain and Protects Cartilage in Rheumatoid Arthritis</p>

Cited by 30 publications

References 50 publications

Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH® Micro-Immunotherapy Treatment

Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTH® Micro-Immunotherapy Treatment

Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis

Intra‐Articular Injectable Biomaterials for Cartilage Repair and Regeneration

Contact Info

Product

Resources

About